Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

THSD7B Activators

Epidermal Growth Factor (EGF) and Insulin-like Growth Factor 1 (IGF-1) are prototypical growth factors that bind to their respective receptor tyrosine kinases, instigating a cascade of phosphorylation events that can lead to the modulation of gene expression, which may encompass THSD7B. Forskolin, known for its capacity to elevate intracellular cyclic AMP (cAMP), activates Protein Kinase A (PKA), a pivotal kinase in multiple signaling pathways that can phosphorylate a broad array of substrates, including transcription factors that govern gene expression, potentially affecting THSD7B levels. PMA is a potent activator of Protein Kinase C (PKC), a family of enzymes that are vital in diverse cellular processes, including the regulation of gene expression; this activation can trigger signaling pathways culminating in altered THSD7B expression. Wnt Agonist 1 activates the Wnt signaling pathway, which is essential for regulating gene transcription and could conceivably induce THSD7B expression. Dibutyryl-cAMP (db-cAMP) operates similarly to Forskolin by mimicking cAMP and activating PKA, which can lead to changes in the transcriptional landscape involving THSD7B.

LY294002, U0126, SB431542, PD98059, and SP600125, despite their primary inhibitory roles on specific kinases or signaling pathways, can lead to complex feedback loops and compensatory mechanisms within cells that might result in the upregulation of certain genes, including THSD7B. For example, LY294002 is a PI3K inhibitor that can affect downstream signaling pathways such as Akt, potentially influencing THSD7B activity. U0126 and PD98059 are inhibitors of MEK, a critical kinase in the MAPK/ERK pathway, which is implicated in the control of gene expression and cellular proliferation. SB431542 inhibits TGF-β signaling, which has wide-ranging effects on gene expression and cellular differentiation and could impact THSD7B expression. SP600125 inhibits JNK, which is involved in stress response signaling and could also affect gene transcription profiles.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

PMA

16561-29-8sc-3576
sc-3576A
sc-3576B
sc-3576C
sc-3576D
1 mg
5 mg
10 mg
25 mg
100 mg
$41.00
$132.00
$214.00
$500.00
$948.00
119
(6)

PMA activates PKC which could influence signal transduction pathways leading to THSD7B expression.

Wnt Agonist

853220-52-7sc-222416
sc-222416A
5 mg
25 mg
$157.00
$609.00
23
(2)

Wnt signaling can regulate gene expression; activating this pathway could affect THSD7B levels.

Dibutyryl-cAMP

16980-89-5sc-201567
sc-201567A
sc-201567B
sc-201567C
20 mg
100 mg
500 mg
10 g
$47.00
$136.00
$492.00
$4552.00
74
(7)

db-cAMP acts as a cAMP analog, enhancing PKA activity and could contribute to the regulation of THSD7B expression.

Roscovitine

186692-46-6sc-24002
sc-24002A
1 mg
5 mg
$94.00
$265.00
42
(2)

As a CDK inhibitor, Roscovitine can alter cell cycle progression and could modulate the expression of THSD7B.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

Inhibiting PI3K with LY294002 can affect downstream signaling pathways and influence THSD7B activity.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

U0126 inhibits MEK, which operates within the MAPK pathway; altering this pathway can impact THSD7B expression.

SB 431542

301836-41-9sc-204265
sc-204265A
sc-204265B
1 mg
10 mg
25 mg
$82.00
$216.00
$416.00
48
(1)

By inhibiting TGF-β signaling, SB431542 can affect transcriptional regulation of genes including THSD7B.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

As an inhibitor of MEK, PD98059 can affect MAPK/ERK pathway and alter gene expression profiles that may encompass THSD7B.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is a JNK inhibitor, modulation of this pathway can lead to changes in gene expression potentially involving THSD7B.